Shock is a serious complication of critical illness and cardiac surgery. Credit: Alexander Grey on Unsplash.

CytoSorbents has received an expanded medical device registration from the Brazilian Health Regulatory Agency (ANVISA) for its CytoSorb blood purification technology for the treatment of shock.

Shock is a serious complication of critical illness and cardiac surgery. It causes a sudden and severe decrease in blood pressure, which can result in organ failure and death due to lack of oxygen and blood flow.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Treatment with CytoSorb helps reverse shock while restoring natural blood pressure in patients.

In September 2020, CytoSorb received its first ANVISA registration for the treatment of cytokine storm in cardiac surgery and critical illnesses such as Covid-19.

It is now available for purchase in Brazil, with Fresenius Medical Care (FMC) responsible for distribution in the Critical Care segment and Contatti Medical in the Cardiac Surgery segment.

See Also:

CytoSorbents CEO Dr Phillip Chan said: “CytoSorb is used across the world in different clinical fields and can be integrated into various extracorporeal platforms to treat life-threatening conditions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are pleased to commercialise CytoSorb in Brazil under this expanded registration through our partners FMC and Contatti Medical, both well-established and connected experts in their respective clinical fields.”

In July this year, CytoSorbents completed the patient recruitment in its pivotal study designed to assess the potential of DrugSorb-ATR to reduce perioperative bleeding in patients undergoing cardiothoracic surgery on AstraZeneca’s blood thinner ticagrelor (Brilinta).

The Safe and Timely Antithrombotic Removal – Ticagrelor (STAR-T) controlled and randomised trial was designed to demonstrate DrugSorb-ATR’s capability in the removal of ticagrelor antithrombotic agent to reduce bleeding.